IROBOT CORP (IRBT)

US4627261005 - Common Stock

8.25  +0.5 (+6.45%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to IRBT. IRBT was compared to 66 industry peers in the Household Durables industry. IRBT has a bad profitability rating. Also its financial health evaluation is rather negative. IRBT does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IRBT has reported negative net income.
In the past year IRBT has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: IRBT reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: IRBT reported negative operating cash flow in multiple years.

1.2 Ratios

Looking at the Return On Assets, with a value of -19.70%, IRBT is doing worse than 90.63% of the companies in the same industry.
Looking at the Return On Equity, with a value of -87.91%, IRBT is doing worse than 90.63% of the companies in the same industry.
Industry RankSector Rank
ROA -19.7%
ROE -87.91%
ROIC N/A
ROA(3y)-24.41%
ROA(5y)-10.32%
ROE(3y)-70.34%
ROE(5y)-35.93%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of IRBT (22.52%) is worse than 71.88% of its industry peers.
IRBT's Gross Margin has declined in the last couple of years.
IRBT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 22.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-22.24%
GM growth 5Y-15.4%

More info and screens

1

2. Health

2.1 Basic Checks

IRBT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IRBT has been increased compared to 1 year ago.
The number of shares outstanding for IRBT has been increased compared to 5 years ago.
IRBT has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 1.02, we must say that IRBT is in the distress zone and has some risk of bankruptcy.
IRBT has a Altman-Z score of 1.02. This is amonst the worse of the industry: IRBT underperforms 81.25% of its industry peers.
A Debt/Equity ratio of 1.24 is on the high side and indicates that IRBT has dependencies on debt financing.
IRBT has a Debt to Equity ratio of 1.24. This is amonst the worse of the industry: IRBT underperforms 82.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF N/A
Altman-Z 1.02
ROIC/WACCN/A
WACC8.88%

2.3 Liquidity

IRBT has a Current Ratio of 1.45. This is a normal value and indicates that IRBT is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of IRBT (1.45) is worse than 79.69% of its industry peers.
IRBT has a Quick Ratio of 1.45. This is a bad value and indicates that IRBT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.94, IRBT perfoms like the industry average, outperforming 48.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.45
Quick Ratio 0.94

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.94% over the past year.
IRBT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.14%.
IRBT shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.01% yearly.
EPS 1Y (TTM)28.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.06%
Revenue 1Y (TTM)-13.14%
Revenue growth 3Y-14.61%
Revenue growth 5Y-4.01%
Sales Q2Q%3.9%

3.2 Future

IRBT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.64% yearly.
The Revenue is expected to decrease by -0.06% on average over the next years.
EPS Next Y35.61%
EPS Next 2Y34.29%
EPS Next 3Y22.64%
EPS Next 5YN/A
Revenue Next Year-21.7%
Revenue Next 2Y-11.86%
Revenue Next 3Y-0.06%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IRBT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRBT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

IRBT's earnings are expected to grow with 22.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.29%
EPS Next 3Y22.64%

More info and screens

0

5. Dividend

5.1 Amount

IRBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IROBOT CORP

NASDAQ:IRBT (1/2/2025, 11:50:00 AM)

8.25

+0.5 (+6.45%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Durables & Apparel
GICS IndustryHousehold Durables
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)01-27 2025-01-27/amc
Inst Owners68.1%
Inst Owner Change0.59%
Ins Owners3.67%
Ins Owner Change22.76%
Market Cap252.12M
Analysts47.5
Price Target11.7 (41.82%)
Short Float %10.37%
Short Ratio2.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)71.85%
Min EPS beat(2)-8.35%
Max EPS beat(2)152.06%
EPS beat(4)3
Avg EPS beat(4)46.13%
Min EPS beat(4)-8.35%
Max EPS beat(4)152.06%
EPS beat(8)4
Avg EPS beat(8)-94.64%
EPS beat(12)6
Avg EPS beat(12)-70.37%
EPS beat(16)9
Avg EPS beat(16)-12.59%
Revenue beat(2)0
Avg Revenue beat(2)-8.32%
Min Revenue beat(2)-13.17%
Max Revenue beat(2)-3.48%
Revenue beat(4)1
Avg Revenue beat(4)-4.33%
Min Revenue beat(4)-13.17%
Max Revenue beat(4)1.44%
Revenue beat(8)2
Avg Revenue beat(8)-10.24%
Revenue beat(12)2
Avg Revenue beat(12)-11.98%
Revenue beat(16)6
Avg Revenue beat(16)-7.37%
PT rev (1m)0%
PT rev (3m)-11.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-122.18%
EPS NY rev (1m)-35.84%
EPS NY rev (3m)-35.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-38.69%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.31
P/FCF N/A
P/OCF N/A
P/B 1.68
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.28
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS26.75
BVpS4.91
TBVpS-0.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.7%
ROE -87.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 22.52%
FCFM N/A
ROA(3y)-24.41%
ROA(5y)-10.32%
ROE(3y)-70.34%
ROE(5y)-35.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-22.24%
GM growth 5Y-15.4%
F-Score3
Asset Turnover1.22
Health
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.42%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.45
Quick Ratio 0.94
Altman-Z 1.02
F-Score3
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)41.4%
Cap/Depr(5y)61.98%
Cap/Sales(3y)1.09%
Cap/Sales(5y)1.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.06%
EPS Next Y35.61%
EPS Next 2Y34.29%
EPS Next 3Y22.64%
EPS Next 5YN/A
Revenue 1Y (TTM)-13.14%
Revenue growth 3Y-14.61%
Revenue growth 5Y-4.01%
Sales Q2Q%3.9%
Revenue Next Year-21.7%
Revenue Next 2Y-11.86%
Revenue Next 3Y-0.06%
Revenue Next 5YN/A
EBIT growth 1Y76.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.55%
EBIT Next 3Y24.01%
EBIT Next 5YN/A
FCF growth 1Y81.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.41%
OCF growth 3YN/A
OCF growth 5YN/A